Image Source: AsiaOne
XWPharma Announces Positive Results from Phase 1 Clinical Trials of XW10172, in Development as Once-Nightly Therapy for Sleep Disorders in Patients with Neurodegenerative DiseasesGlobeNewswireJune 14, 2021Phase 1 Results Demonstrate Optimal Pharmacokinetics, with Rapid Oral Absorption, Prompt Release of Oxybate from the New Chemical Entity XW10172, and Sustained Duration at Desired Plasma Concentrations Suitable for Once-Nightly Dosing Data Support Continued Development of XW10172; Phase 2 Trial in Sleep Disorders in Patients with Parkinson’s Disease is planned to start 3Q2021 followed by Single Registrational Trial in Narcolepsy Results Selected for Podium Presentation at SLEEP 2021, the Annual Meeting of the Associated Professional Sleep Societies
Source: AsiaOne